On 14 September 2026, LIGENT TECHNOLOGIES (09856.HK) published a prospectus to launch its global offering at an offer price of HKD 32.96 per share, comprising 172,014,700 offer shares subject to the over-allotment option, of which 17,201,500 shares are under the Hong Kong offering and 154,813,200 shares under the international offering; net proceeds are estimated at approximately HKD 5,445.3 million after estimated expenses, or approximately HKD 6,295.7 million if the over-allotment option is exercised in full. The shares are expected to commence trading on the Main Board of the Stock Exchange at 9:00 a.m. on 22 September 2026.
On 11 September 2026, CLARITY MEDICAL (01406.HK) announced the key findings of the forensic investigation into the IPO allegations and the independent internal control review, with the forensic investigation report by Grant Thornton finding insufficient evidence that the Group's profitability had been manipulated for the purpose of a false listing; the Group has adopted and implemented all recommended remediation measures. Trading in the Company's shares has been suspended since 15 April 2025 and will continue to be suspended.
On 11 September 2026 (after trading hours), HINSANG GROUP (06893.HK) announced that its indirect wholly-owned subsidiary entered into a provisional agreement with Tin Shing Group Holdings Limited to dispose of Workshops 1–19 on the fifth floor of Block A of Shatin Industrial Centre (together with the flat roofs) and a car parking space at Nos. 5–7 Yuen Shun Circuit, Shatin, Hong Kong for a cash consideration of HK$98,000,000; the Disposal constitutes a major transaction subject to shareholders' approval.
On 11 September 2026, TRIGIANT (01300.HK) announced that its indirect wholly-owned subsidiary has succeeded in the bid on the Chongqing Assets and Equity Exchange for the acquisition of 100% equity interests in Qinghai Zhongli Optical Fibre Technology Co., Ltd. from the Vendor at a consideration of RMB455 million (equivalent to approximately HK$526 million); the Target Company is principally engaged in the production and sales of optical fibre preforms, optical fibres and optical fibre connectors.
On 11 September 2026, XH NEWS MEDIA (00309.HK) announced that it has come to its attention that the Petitioner, Mr. Tsui Kwok Hing, filed a winding-up petition with the High Court of Hong Kong on the same day on the ground that the Company is indebted to him in the outstanding sum of HK$4,050,363.59 in respect of directors' advances; the Petition is scheduled to be heard before the High Court on 2 December 2026.
On 11 September 2026, CHIHO ENV (00976.HK) issued a supplemental announcement in relation to its announcement dated 1 June 2026 concerning the removal of the office of an executive director (Mr. Qin), disclosing that Mr. Qin subsequently made several allegations against the Company and, on 24 July 2026, commenced proceedings before the Labour Tribunal for a claim in the amount of HK$3,066,986.29 or, as an alternative, an award for terminal payments to be assessed.
On 11 September 2026, PEIJIA-B (09996.HK) announced that the Company's internally developed GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System has recently received approval from the National Medical Products Administration of the People's Republic of China for its registration application; the Company said the approval marks the Group's entry into the commercial treatment of mitral regurgitation.
On 11 September 2026, VOBILE GROUP (03738.HK) made a voluntary announcement that a subsidiary of the Group has entered into a collaboration agreement with Ant Digital Technology to build a copyright large model, creating an intelligent foundation for digital content in the AI (artificial intelligence) era.
On 11 September 2026, MAN SANG INT'L (00938.HK) announced that Mr. Wong Chun Kit has resigned as the chief financial officer, company secretary and authorised representative of the Company with effect from 13 September 2026; the Board has appointed Mr. Ho Yu to take up the three positions from the same date.
On 11 September 2026, RIDGE OUTDOOR (02720.HK) announced that Ms. Gao Shan has tendered her resignation as the financial controller of the Company with effect from September 11, 2026; Ms. Lei Yang, the executive Director and general manager of the Company, will assume the duties and responsibilities of the financial controller from the same date.
On 11 September 2026, CHINA STAR ENT (00326.HK) announced that HWKFEL, the controlling shareholder jointly held by Chairman Heung Wah Keung and Vice Chairman Chen Ming Yin, Tiffany, entered into a sale and purchase agreement with Ms. Lam Sin Cheng to dispose of 340 million shares, representing approximately 14.00% of the entire issued share capital; upon completion, HWKFEL's stake will fall from approximately 64.20% to approximately 50.20% and it will remain the controlling shareholder.
On 11 September 2026, TIGERMED (03347.HK) announced that its actual controllers Ye Xiaoping and Cao Xiaochun received on the same day a warning letter and a Prior Notice of Administrative Penalty (Zhe Zheng Fa Zi [2026] No. 21) issued by the Zhejiang Regional Office of the CSRC, and that the two are proposed to be given a warning and fined RMB 1 million in aggregate for suspected violations in information disclosure relating to changes in shareholding.
On 11 September 2026, SINO-OCEAN GP (03377.HK) provided an inside information update on the failure of its wholly-owned subsidiary Beijing Sino-Ocean Holdings Group to repay matured debts and on its litigation: as at 31 August 2026, its matured and unpaid borrowings totalled RMB 16.694 billion (compared with RMB 18.160 billion at the end of 2025), increasing by RMB 294 million during August, with no new major litigation in August 2026 and one case remaining as a dishonest judgment debtor.
On 11 September 2026, LIVZON PHARMA (01513.HK) announced that Mr. Zhu Baoguo resigned as chairman, a non-executive director, chairman of the strategy committee, chairman of the environmental, social and governance committee and the Company's legal representative on retirement, ceasing to hold any position in the Group while remaining the Company's actual controller; on the nomination committee's recommendation, President Mr. Liu Daping has been appointed as chairman and chairman of both committees for a term ending on the expiry of the twelfth session of the Board.
On 11 September 2026, HENGRUI PHARMA (01276.HK) announced that Ruzaltatug Rezetecan for Injection (SHR-A2009 for Injection) of its subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. has been included in the breakthrough therapy designation list by the Center for Drug Evaluation of the National Medical Products Administration, for use in combination with bevacizumab in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have failed prior EGFR TKI treatment.
On 11 September 2026, SUNEVISION (01686.HK) announced that the wholly-owned subsidiary of its controlling shareholder, Sun Hung Kai Properties, has exercised its rights to convert all of its convertible notes in an aggregate amount of HKD 171,942,750.00 into 1,719,427,500 new shares, with the conversion date set at 27 October 2026, and that the public float of the Company will decrease to approximately 15.1029%.
